iCAR Bio Therapeutics Ltd.
10
1
1
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 10 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)
Role: collaborator
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Role: collaborator
Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances
Role: collaborator
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Role: collaborator
CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies
Role: collaborator
Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies
Role: collaborator
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Role: collaborator
BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma
Role: collaborator
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
Role: collaborator
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
Role: collaborator
All 10 trials loaded